| Name
|
Charybdotoxin
|
| Code
|
[95751-30-7]
|
| The alias
|
Charybdotoxin
|
| Sequence (single letter abbreviation)
|
Glp-FTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS(Cys7 and Cys28/Cys13 and Cys33/Cys17 and Cys35 Bridge)
|
| Sequence (three-letter abbreviation)
|
Glp-Phe-Thr-Asn-Val-Ser-Cys-Thr-Thr-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Gln-Arg-Leu-His-Asn-Thr-Ser-Arg-Gly-Lys-Cys-Met-Asn-Lys-Lys-Cys-Arg-Cys-Tyr-Ser-OH (trifluoroacetate salt)(Cys7 and Cys28/Cys13 and Cys33/Cys17 and Cys35 Bridge)
|
| A basic description
|
This highly immunogenic undecapeptide generates hCGspecific antibodies
|
| solubility
|
|
| The molecular weight
|
4295.95
|
| Chemical formula
|
C176H277N57O55S7
|
| The purity
|
80%，90%，95%，98%，99%
|
| Weight
|
1mg,5mg,10mg,50mg,100mg,1g
|
| Storage conditions
|
Store at -20°C. Keep tightly closed. Store in a cool dry place.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
G.Gimenez-Gallego et al., Proc. Natl. Acad. Sci. USA, 85, 3329 (1988)
R.MacKinnon and C.Miller, Science, 245, 1382 (1989)
N.A.Castle et al., Trends Neurosci., 12, 59 (1989)
T.R.Werkman et al., Neuroscience, 50, 935 (1992)
T.R.Jones et al., J. Appl. Physiol., 74, 1879 (1993)
C.Miller, Neuron, 15, 5 (1995)
K.G.Chandy et al., Trends Pharmacol. Sci., 25, 280 (2004)
|
| The C-terminal
|
|
| The N-terminal
|
|
| Chemical bridge
|
(Cys7 and Cys28/Cys13 and Cys33/Cys17 and Cys35 Bridge)
|